Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes.
Showing 5 out of 5 products:
The final regression models for White and Black patients (Fig. 1) included age, weight, prosthetic valves, amiodarone use, CYP2C9*3, and VKORC1 (show VKORC1 Proteins) 3673 G>A genotypes as covariates, whereas possession of CYP2C9*2 and simvastatin use were retained in the final model for White, but not Black patients.
The present study confirms the variable distribution of CYP2C8 (show CYP2C8 Proteins) (*2 and *3) and CYP2C9 (*2 and *3) allelic polymorphisms among South Indian diabetic populations.
Our results further support a minor contribution of CYP2C9 genetic variability toward steady-state endoxifen concentrations. Integration of clinician and genetic variables into individualized tamoxifen dosing algorithms would marginally improve their accuracy and potentially enhance tamoxifen treatment outcomes.
CYP2C9 genetic variation was associated with long-term overall mortality and non-major bleeding in elderly patients treated with vitamin K antagonists.
Until the age of 19, weight has a far greater effect on Vitamin K antagonist dosing variation than VKORC1 (show VKORC1 Proteins) and CYP2C9 polymorphisms. During the age of 20-40years, VKORC1 (show VKORC1 Proteins) and CYP2C9 polymorphisms play a significant role.
CYP2C9*3 did show significant effect on warfarin dose requirement
Two SNPs in CYP2C9, rs2153628 and rs1799853 are associated with response to indomethacin for the treatment patent ductus arteriosus.
the carriership of individual C and T alleles in the case of CYP2C9*2 gene, as well as A and C for CYP2C9*3 is not a predictor of antiretroviral drug-induced liver injury.
Genetic polymorphisms in CYP2C9 cause significant interindividual variability in the metabolism of its substrates. This study estimated the coefficient of variation (CV) for the intrinsic hepatic clearance of tolbutamide by CYP2C9 for each CYP2C9 genotype using previously reported area under the blood concentration curve (AUC) and oral clearance (CLoral) values in a Monte Carlo simulation with a dispersion model.
These results suggest that genetic polymorphisms of CYP2C9 enzymes result in the production of varying levels of biologically active JWH-018 metabolites in some individuals, offering a mechanistic explanation for the diverse clinical toxicity often observed following JWH-018 abuse.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P-450 S-mephenytoin 4-hydroxylase
, cytochrome P-450MP
, cytochrome P450 2C9
, cytochrome P450 PB-1
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase